Vanguard Portfolio Management’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$646M Sell
2,189,157
-21,822
-1% -$5.75M 0.03% 568
2026
Q2
$501M Sell
2,210,979
-83,691
-4% -$14.9M 0.02% 709
2026
Q1
$396M Buy
+2,294,670
New +$425M 0.02% 756

Other funds holding CRL

Vanguard Portfolio Management's CRL Position: Q3 2026 in Review

Vanguard Portfolio Management reduced its Charles River Laboratories (CRL) stake by 0.99% in Q3 2026, selling an estimated $5.75M and leaving 2,189,157 shares worth $646M. The position accounts for 0.03% of the portfolio, ranked #568.

Vanguard Portfolio Management first reported a position in CRL in Q1 2026 and has held it in 3 quarters since. 646 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • Vanguard Portfolio Management held 2,189,157 shares of Charles River Laboratories worth $646M as of Q3 2026.
  • Vanguard Portfolio Management sold 21,822 Charles River Laboratories shares in Q3 2026, an estimated $5.75M.
  • Charles River Laboratories made up 0.03% of Vanguard Portfolio Management's portfolio in Q3 2026, its #568 holding.
  • Vanguard Portfolio Management first reported a position in Charles River Laboratories in Q1 2026 and has held it in 3 quarters since.
  • 646 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Vanguard Portfolio Management's 13F filing for Q3 2026, filed 13 Nov 2026.